




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 285/14, A61K 31/445, C07D 271/12, 413/06, A61K 31/535, C07D 417/06, A61K 31/54, C07D 498/10	A1	(11) International Publication Number: WO 98/35950 (43) International Publication Date: 20 August 1998 (20.08.98)
(21) International Application Number: PCT/US98/02713 (22) International Filing Date: 13 February 1998 (13.02.98) (30) Priority Data: 08/800,108 13 February 1997 (13.02.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/800,108 (CIP) Filed on 13 February 1997 (13.02.97) (71) Applicant (for all designated States except US): CORTEX PHARMACEUTICALS, INC. [US/US]; 15241 Barranca Parkway, Irvine, CA 92718 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ⁽ⁱ⁾ ROGERS, Gary, A. [US/US]; 3056 Foothill Road, Santa Barbara, CA 93105 (US); MARRS, Christopher, M. [US/US]; 2 Parterre Avenue, Foothill Ranch, CA 92610 (US). (74) Agents: GORTHEY, LeeAnn et al.; Dehlinger & Associates, LLP, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY (57) Abstract Compounds of general structural formula (I) are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors dependent upon AMPA receptors, and in treating conditions, such as memory impairment, in which AMPA receptors, or synapses utilizing these receptors, are reduced in numbers or efficiency. They may also be used to enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior.  (I)		